Individual use of antiasthmatic drugs in the European Community Respiratory Health Survey

European Respiratory Journal

Volumn 12, Issue 3, 1998, Pages 557-563

  Janson, C ^a   Chinn, S ^b   Jarvis, D ^b   Burney, P ^b,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b G   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Asthma; Atopy; Bronchial hyperresponsiveness; Drug utilization; Smoking; Socioeconomic status

Indexed keywords

ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; EUROPEAN UNION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGE DISTRIBUTION; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; DRUG UTILIZATION; EUROPEAN UNION; FEMALE; HEALTH SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; RANDOM ALLOCATION; RISK FACTORS; SEX DISTRIBUTION; SMOKING; SOCIOECONOMIC FACTORS;

EID: 0031657063     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12030557     Document Type: Article

References (29)

1. Burney PGJ, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. Eur Respir J 1994; 7: 954-960.
2. United Medical and Dental Schools of Guy's and St Thomas's Hospitals. Department of Public Health Medicine. London, protocol for the European Community Respiratory Health Survey, 1993.
3. European Community Respiratory Health Survey. The prevalence of respiratory symptoms in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9: 687-695.
4. European Community Respiratory Health Survey. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J Allergy Clin Immunol 1997; 99: 314-322.
5. European Community Respiratory Health Survey. Variation in bronchial responsiveness in the European Community Health Survey. Eur Respir J 1997; 10: 2495-2501.
6. European Community Respiratory Health Survey. Physician diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 1795-1802.
7. Nordic Council on Medicines. Nordic Statistics on Medicines 1990-1992. Upsala NLN publication No 34, 1993.
8. Kesten S, Rebuck AS, Chapman KR. Trends in asthma and chronic obstructive therapy in Canada 1985 to 1990. J Allergy Clin Immunol 1993; 92: 499-506.
9. Sly RM. Changing asthma mortality and sales of inhaled bronchodilators and antiasthmatic drugs. Ann Allergy 1994; 73: 439-443.
10. Van Ganse E, Van der Linden PD, Leufkens HGM, Herings RMC, Vincken W, Ernst P. Asthma medication and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8: 1856-1860.
11. Ruggieri F, Hindle M. Diagnosis and treatment of asthma across Europe. Eur Respir J 1989; 2: Suppl. 6, 536s-539s.
12. Vermeire P. Differences in asthma management around the world. Eur Respir Rev 1994; 4: 279-281
13. Björnsson E, Janson C, Håkansson L, Enander I, Venge P, Boman G. Serum eosinophil cationic protein in relation to bronchial asthma in a young Swedish population. Allergy 1994; 49: 730-736.
14. Janson C, De Backer W, Gislason T, et al. Increased prevalence of sleep disturbances and daytime sleepiness in subjects with bronchial asthma: a population study of young adults in three European countries. Eur Respir J 1996; 9: 2132-2138.
15. European Community for Coal and Steel. Standardization of lung function tests. Clin Respir Phys 1983; 19: Suppl. 5: 22-27.
16. Classification of Occupations 1980. Office of Population Censuses and Surveys. London, Her Majesty's Stationery Office, 1980.
17. Francis B, Green M, Payne C, eds. The GLIM system release 4 manual. Oxford, Clarendon Press, 1993.
18. Troisi RJ, Speizer FE, Rosner B, Trichopondos D, Willett WC. Cigarette smoking and incidence of chronic bronchitis and asthma in women. Chest 1995; 108: 1557-1561.
19. Pedersen B, Dahl R, Karlström R, Peterson CGB, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996; 153: 1519-1529.
20. Gibson P, Henry D, Francis L, et al. Association between availability of non-prescription beta2-agonist inhalers and under treatment of asthma. BMJ 1993; 306: 1514-1518.
21. Boëthius G. Utilization of anti-asthmatic drugs in Sweden: review of sales and prescription data 1975-1991. In: Strandberg K, Beerman B, Lönnerholm G, eds. Pharmacological Treatment of Bronchial Asthma. Uppsala Swedish Medical Products Agency, 1993; pp. 7-17.
22. Gislason T, Olafsson O, Sigvaldason A. Users of anti asthma drugs in Iceland: a drug utilization study. Eur Respir J 1997; 10: 1230-1234.
23. Awadh N, Chu S, Grunfeld A, Simpson K, FitzGerald JM. Comparison of males and females presenting with acute asthma to the emergency department. Respir Med 1996; 90: 485-489.
24. Halras J, Hansen N-C G. Individual utilization of anti-asthma medication by young adults: a prescription database analysis. J Intern Med 1993; 234: 65-70.
25. Larsson L, Boethius B, Uddenfeldt M. Differences in utilization of asthma drugs between two neighbouring Swedish provinces: relation to symptom reporting. Eur Respir J 1993; 6: 198-203.
26. Roberts SJ, Bateman DN. Which patients are prescribed inhaled anti-asthma drugs? Thorax 1994; 49: 1090-1095.
27. Strachan DP, Anderson HR, Limb ES, O'Neill AO, Wells N. A national survey of asthma prevalence, severity and treatment in Great Britain. Arch Dis Child 1994; 70: 174-178.
28. National Heart, Lung, and Blood Institute, National Institute of Health. International Consensus Report on the diagnosis and management of asthma. NIH publication number 92-3091, 1992.
29. National Institute of Health, National Heart, Lung, and Blood Institute. Global Initiative for asthma. NIH publication number 95-3659, 1995.